Reply
Jessica Musto, Michael R. Lucey, John Rice – 9 December 2021
NASHFit: A randomized controlled trial of an exercise training program to reduce clotting risk in patients with NASH
Jonathan G. Stine, Ian R. Schreibman, Alison J. Faust, Jessica Dahmus, Benjamin Stern, Christopher Soriano, Gloriany Rivas, Breianna Hummer, Scot R. Kimball, Nate R. Geyer, Vernon M. Chinchilli, Rohit Loomba, Kathryn Schmitz, Christopher Sciamanna – 9 December 2021
MutT Homolog 1 Inhibitor Karonudib Attenuates Autoimmune Hepatitis by Inhibiting DNA Repair in Activated T Cells
Yong Chen, Xiangwei Hua, Bingyuan Huang, Stella Karsten, Zhengrui You, Bo Li, You Li, Yikang Li, Jubo Liang, Jun Zhang, Yiran Wei, Ruiling Chen, Zhuwan Lyu, Xiao Xiao, Min Lian, Jue Wei, Jingyuan Fang, Qi Miao, Qixia Wang, Ulrika Warpman Berglung, Ruqi Tang, Thomas Helleday, Xiong Ma – 9 December 2021 – Autoimmune hepatitis (AIH) is an inflammatory liver disease driven by the hyperactivation of various intrahepatic antigen‐specific T cells due to a breach of immune tolerance.
A NET gain in our understanding of acute liver failure
Moira B. Hilscher, Vijay H. Shah – 9 December 2021
Rise above the stress—Endoplasmic reticulum stress and autophagy enhance the release of hepatitis B virus subparticles
Lei Wei, Alexander Ploss – 9 December 2021
Letter to the editor: Reactivation of HBV triggered by SARS‐CoV‐2 in a patient with cirrhosis
Marta Librero Jiménez, María Ángeles López Garrido, María Carmen Fernández Cano – 7 December 2021
Effect of increased alcohol consumption during COVID‐19 pandemic on alcohol‐associated liver disease: A modeling study
Jovan Julien, Turgay Ayer, Elliot B. Tapper, Carolina Barbosa, William N. Dowd, Jagpreet Chhatwal – 7 December 2021
Reply
Brian J. McMahon – 6 December 2021